BLOG

New type of checkpoint inhibitor offers early promise against tumors, but will it last?

A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing early signs of halting tumor growth in patients with advanced cancer, offering hope that more patients might one day benefit from cancer immunotherapy.